These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11239866)

  • 21. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma.
    Tamada Y; Taniguchi T; Murase H; Yamamoto T; Kitazawa Y
    J Ocul Pharmacol Ther; 2001 Feb; 17(1):19-25. PubMed ID: 11322634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status of prostaglandin therapy: latanoprost and unoprostone.
    Susanna R; Chew P; Kitazawa Y
    Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S97-104. PubMed ID: 12204705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit.
    Kaufman HE; Varnell ED; Toshida H; Kanai A; Thompson HW; Bazan NG
    Am J Ophthalmol; 2001 May; 131(5):643-6. PubMed ID: 11336941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients.
    Toris CB; Zhan G; Camras CB
    Arch Ophthalmol; 2004 Dec; 122(12):1782-7. PubMed ID: 15596580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
    Stewart WC; Stewart JA; Day DG; Jenkins J
    Acta Ophthalmol Scand; 2004 Apr; 82(2):161-5. PubMed ID: 15043534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
    Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
    Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
    Hommer A; Kapik B; Shams N;
    Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
    Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
    Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone).
    Yamamoto T; Kitazawa Y; Azuma I; Masuda K
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S99-103. PubMed ID: 9154284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol.
    Konstas AG; Nakos E; Tersis I; Lallos NA; Leech JN; Stewart WC
    Am J Ophthalmol; 2002 Jun; 133(6):753-7. PubMed ID: 12036665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional reduction in intraocular pressure achieved with latanoprost in normal-tension glaucoma patients previously treated with unoprostone.
    Enoki M; Saito J; Hara M; Uchida T; Sagara T; Nishida T
    Jpn J Ophthalmol; 2006; 50(4):334-337. PubMed ID: 16897217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching to latanoprost monotherapy for 24 weeks in glaucoma patients.
    Takahashi I; Tanaka M
    Eur J Ophthalmol; 2004; 14(5):401-6. PubMed ID: 15506602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
    Sharpe ED; Henry CJ; Mundorf TK; Day DG; Stewart JA; Jenkins JN; Stewart WC
    Eye (Lond); 2005 Jan; 19(1):35-40. PubMed ID: 15094733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension.
    Nordmann JP; Rouland JF; Mertz BP
    Curr Med Res Opin; 1999; 15(2):87-93. PubMed ID: 10494491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH; Feldman RM; Sheu WP;
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost.
    Stewart WC; Day DG; Sharpe ED; Dubiner HB; Holmes KT; Stewart JA
    Am J Ophthalmol; 1999 Dec; 128(6):692-6. PubMed ID: 10612504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma.
    Konstas AG; Maltezos AC; Gandi S; Hudgins AC; Stewart WC
    Am J Ophthalmol; 1999 Jul; 128(1):15-20. PubMed ID: 10482089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical evaluation of isopropyl unoprostone (Rescula), in the adjunctive treatment of primary open angle glaucoma].
    Zarnowski T; Kawa P; Jurkowska-Dudzińska J; Zagórski Z
    Klin Oczna; 2001; 103(1):13-5. PubMed ID: 11605578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.